Chronic myelogenous leukemia: molecular monitoring in clinical practice

Cover Page

Cite item

Full Text

Abstract

Use of tyrosine kinase inhibitor imatinib has led to significant progress in chronic myeloid leukemia (CML) treatment. To date, genetic monitoring is a mandatory attribute of therapy with tyrosine kinase inhibitors. The purpose of this study was to access the imatinib therapy efficacy in CML patients using complete molecular genetic monitoring by standard cytogenetics, realtime polymerase chain reaction and mutational analysis. Correlation between cytogenetic and molecular response was shown. Heterogeneity of molecular response in each patient group was revealed by expression of BCR-ABL. Kinase domain mutations were detected in 32 % of CML patients resistant to imatinib.

About the authors

N. R. Ryabchikova

Bashkortostan State Medical University, Ministry of Health of Russia

Russian Federation

I. R. Minniakhmetov

Institute of Biochemistry and Genetics, Ufa Scientific Center, Russian Academy of Sciences

Russian Federation

G. Sh. Safuanova

Bashkortostan State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: safuanova@bk.ru
Russian Federation

D. V. Islamgulov

Institute of Biochemistry and Genetics, Ufa Scientific Center, Russian Academy of Sciences

Russian Federation

A. S. Karunas

Institute of Biochemistry and Genetics, Ufa Scientific Center, Russian Academy of Sciences

Russian Federation

E. E. Khusnutdinova

Institute of Biochemistry and Genetics, Ufa Scientific Center, Russian Academy of Sciences

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2013



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.